Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "licensing"

223 News Found

Dr Fabrice Egros gets an additional role at Lupin
People | February 23, 2022

Dr Fabrice Egros gets an additional role at Lupin

He will continue to lead business in LATAM and Asia regions in this new role


VitaDAO and Molecule AG partner with Apollo Health Ventures to build the longevity biotech & Web3 ecosystem
Supply Chain | February 21, 2022

VitaDAO and Molecule AG partner with Apollo Health Ventures to build the longevity biotech & Web3 ecosystem

By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem


Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation
News | February 19, 2022

Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study


ITM receives investment of EUR 25 mn from Grand Pharma
News | February 18, 2022

ITM receives investment of EUR 25 mn from Grand Pharma

Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China


Launches and margin sustainability hold key for Glenmark: ICICI Direct
News | February 15, 2022

Launches and margin sustainability hold key for Glenmark: ICICI Direct

Key takeaways of Q3FY22 quarter & conference call highlights


Glenmark to commercialize AstraZeneca’s asthma drug in Columbia
Biotech | February 14, 2022

Glenmark to commercialize AstraZeneca’s asthma drug in Columbia

AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia


Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
Drug Approval | January 21, 2022

Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir

The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list


Glenmark Specialty S.A. partners with Lotus to commercialise Ryaltris in key Asian markets
News | January 20, 2022

Glenmark Specialty S.A. partners with Lotus to commercialise Ryaltris in key Asian markets

The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus


Abbisko Therapeutics enters global tie-up with Lilly to develop novel molecules
Biotech | January 18, 2022

Abbisko Therapeutics enters global tie-up with Lilly to develop novel molecules

The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise


Glenmark receives U.S. FDA approval for Ryaltris
Drug Approval | January 14, 2022

Glenmark receives U.S. FDA approval for Ryaltris

The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily